Karrasch M.,Friedrich - Schiller University of Jena |
Recent Patents on Anti-Cancer Drug Discovery | Year: 2015
Specific elimination of tumor cells by replication-competent viral vectors is mediated through active viral replication, spread in tumor tissue and direct cytopathic effects. In addition, immune responses are induced against virally infected tumor cells. Recently, oncolytic vectors were constructed with mutations in neurovirulence genes or DNA synthesis genes. Viral replication should only be restricted to malignant cells to prevent severe viral disease. These constructed vectors terminate cells by mechanisms different from standard anti-cancer therapies; they offer another treatment modality which can be used in combination with chemotherapy, radiotherapy and gene therapies with additive or synergistic effects. Combination therapies are usually necessary to control tumorigenic diseases. Inhibiting angiogenesis represents another new field in current anticancer treatment development. Combining an oncolytic virus with antiangiogenesis is able to potentiate both treatment effects compared to each treatment modality alone in both primary and advanced disease. This combination might be beneficial for cancer patients in the future. We have also outlined some relevant patents. © 2013 Bentham Science Publishers.
Bohmer N.,Charite - Medical University of Berlin |
Jordan A.,Charite - Medical University of Berlin |
Beilstein Journal of Nanotechnology | Year: 2015
Nanomedicine is a rapidly growing field in nanotechnology, which has great potential in the development of new therapies for numerous diseases. For example iron oxide nanoparticles are in clinical use already in the thermotherapy of brain cancer. Although it has been shown, that tumor cells take up these particles in vitro, little is known about the internalization routes. Understanding of the underlying uptake mechanisms would be very useful for faster and precise development of nanoparticles for clinical applications. This study aims at the identification of key proteins, which are crucial for the active uptake of iron oxide nanoparticles by HeLa cells (human cervical cancer) as a model cell line. Cells were transfected with specific siRNAs against Caveolin-1, Dynamin 2, Flotillin-1, Clathrin, PIP5Ka and CDC42. Knockdown of Caveolin-1 reduces endocytosis of superparamagnetic iron oxide nanoparticles (SPIONs) and silica-coated iron oxide nanoparticles (SCIONs) between 23 and 41%, depending on the surface characteristics of the nanoparticles and the experimental design. Knockdown of CDC42 showed a 46% decrease of the internalization of PEGylated SPIONs within 24 h incubation time. Knockdown of Dynamin 2, Flotillin-1, Clathrin and PIP5Ka caused no or only minor effects. Hence endocytosis in HeLa cells of iron oxide nanoparticles, used in this study, is mainly mediated by Caveolin-1 and CDC42. It is shown here for the first time, which proteins of the endocytotic pathway mediate the endocytosis of silica-coated iron oxide nanoparticles in HeLa cells in vitro. In future studies more experiments should be carried out with different cell lines and other well-defined nanoparticle species to elucidate possible general principles. © 2015 Bohmer and Jordan.
MagForce | Date: 2015-09-09
The present invention relates to compositions containing nanoparticies and uses of said composition for transferring therapeutically active substances into cells by means of specifically coated nanoparticles. The chemical design of the particles is such that a large amount thereof is absorbed into the cells. No direct bond between nanoparticle and the therapeutically active substance is required for the transfer into the cells. Thanks to said transfer, an increased efficacy of the substance and simultaneously reduced systemic toxicity is achieved, i.e. an increase in the efficacy while the side effects are reduced.
Agency: Cordis | Branch: FP7 | Program: CP-FP | Phase: NMP-2008-1.1-1 | Award Amount: 4.86M | Year: 2009
The aim of this project is the assembly and the fabrication of a new generation of multifunctional nanostructures for performing combined hyperthermia and controlled drug release, specifically targeted to cancer cells. The magnetic nanocontainers we intend to develop can perform at the same time cell recognition, hyperthermia treatment, and, as a consequence of the heat and /or cell environment stimuli, the release of drug with high selectivity for ovarian carcinoma. These multifunctional tasks are made possible due to the inclusion of three main components: a) the magnetic nanoparticles, allowing detection by MRI, cancer treatment by hyperthermia and providing stimuli for drug release; b) the nanocontainers, which allow for drug encapsulation and protection from degradation, facilitate the release of the drug upon application of an external stimulus, such as heat, or an internal one, such as the acidic pH of the tumour cells; c) the antibody fragments attached to the surface of the magnetic nanocontainers to deliver them selectively to the ovarian cancer cells. The individual building blocks and their assemblies will be characterized with respect to physical, chemical, and biological features, followed by dissemination of the newly acquired knowledge. Cell culture experiments will allow to understand the performance of such nano-tools in vitro. Directed towards application in patients, in vivo animal studies will be carried out on the most successful magnetic nanocontainers. The objectives of this proposal cover a wide range of scientific fields, hence a truly interdisciplinary collaboration between chemists, physicists, and biologists is required. To this end, we propose a european network collaboration between academic partners, who will take care of the development of new solutions for nanofabrication, and industrial partners implied in the field of the proposed application who will evaluate/develop the materials and act as advisors for risks arising during the project.
News Article | May 21, 2015
BERLIN & CARSON CITY, Nev.--(BUSINESS WIRE)--MagForce USA, Inc., a majority owned subsidiary of MagForce AG (Frankfurt, Entry Standard, XETRA: MF6, ISIN: DE000A0HGQF5), a leading medical device company in the field of nanomedicine focused on oncology, announced today it has filed an Investigational Device Exemption (IDE) with the USA Food and Drug Administration (FDA). The study treatment uses MagForce's proprietary NanoTherm(TM) technology to completely ablate prostate cancer lesions. This IDE submission follows the submission of our pre-IDE submission to FDA in November, 2014 and a subsequent in-person meeting with FDA in January, 2015. The purpose of the proposed study that will enroll up to 120 men is to demonstrate that NanoTherm(TM) can ablate cancer lesions for patients who have Gleason Score 7 prostate cancer and are under active surveillance. By ablating the lesions, patients will be able to maintain active surveillance and avoid surgery and other treatments all with well-known side effects like impairment of urinary and sexual functions. Dr. Ian M. Thompson, Jr., Director, Cancer Therapy and Research Center, a National Cancer Institute-designated Cancer Center at the University of Texas Health Science Center at San Antonio and Dr. Dan W. Lin, Chief of Urologic Oncology and Professor in the Department of Urology at the University of Washington School of Medicine in Seattle have agreed to be Co-Principal Investigators. Larry Kessler, Sc.D., Professor and Chair of the Department of Health Services, School of Public Health at the University of Washington is also a Co-Investigator overseeing the Regulatory Submission and Registration processes. "This is indeed a significant milestone for MagForce USA, Inc. and MagForce AG. Potentially 100,000 men in active surveillance programs could benefit from this Focal therapy after registration in the USA. We believe the registration clinical trial will prove that NanoTherm(TM) therapy can fulfill the desired outcome. We look forward to working with the FDA and advancing the registration process in the USA.," Dr. Ben J. Lipps added. About MagForce AG and MagForce USA, Inc. MagForce AG, listed in the entry standard of the Frankfurt Stock Exchange (MF6, ISIN: DE000A0HGQF5), together with its subsidiary MagForce USA, Inc. is a leading medical device company in the field of nanomedicine focused on oncology. The Group's proprietary NanoTherm(TM) therapy enables the targeted treatment of solid tumors through the intratumoral generation of heat via activation of superparamagnetic nanoparticles. Mithril Capital Management, a growth-stage technology fund founded by Ajay Royan and Peter Thiel, along with MagForce AG, are investors and strategic partners in MagForce USA, Inc. NanoTherm(TM), NanoPlan(R), and NanoActivator(R) are components of the therapy and have received EU-wide regulatory approval as medical devices for the treatment of brain tumors. MagForce, NanoTherm(TM), NanoPlan(R), and NanoActivator(R) are trademarks of MagForce AG in selected countries. For more information, please visit: www.magforce.com Get to know our Technology: video (You Tube) Stay informed and subscribe to our mailing list. This release may contain forward-looking statements and information which may be identified by formulations using terms such as "expects", "aims", "anticipates", "intends", "plans", "believes", "seeks", "estimates" or "will". Such forward-looking statements are based on our current expectations and certain assumptions, which may be subject to a variety of risks and uncertainties. The results actually achieved by MagForce AG may substantially differ from these forward-looking statements. MagForce AG assumes no obligation to update these forward-looking statements or to correct them in case of developments, which differ from those, anticipated. Language: English Company: MagForce AG Max-Planck-Straße 3 12489 Berlin Germany Phone: +49 (0)30 308 380 0 Fax: +49 (0)30 308 380 99 E-mail: firstname.lastname@example.org Internet: www.magforce.com ISIN: DE000A0HGQF5 WKN: A0HGQF Listed: Regulated Unofficial Market in Berlin, Dusseldorf, Stuttgart; Open Market (Entry Standard) in Frankfurt End of News DGAP News-Service